Erbin Antagonists Modulate ErbB2 Activity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for ErbB2-related disorders, such as breast cancer and neurological conditions, face challenges including cardiac dysfunction and limited treatment options for ErbB2-mediated disorders, particularly in cases of overexpression or misregulation of ErbB2.
Innovation Solution
Modulating the interaction between ErbB2 and Erbin by using Erbin antagonists or agonists to stabilize or inhibit ErbB2 activity, which can be achieved through polypeptides, aptamers, RNAi, antibodies, or small molecules that bind to Erbin or ErbB2, thereby reducing or enhancing ErbB2 biological activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If trastuzumab is used to treat ErbB2-overexpressing breast cancer, then tumor growth is inhibited, but cardiac dysfunction occurs
Solution Approach 1:
The patent introduces Erbin antagonists as intermediary molecules that indirectly modulate ErbB2 activity by disrupting the Erbin-ErbB2 interaction, rather than directly binding to ErbB2 like trastuzumab. This intermediary approach allows for alternative signaling pathway modulation that spares cardiac function while maintaining anti-cancer efficacy
Solution Approach 2:
The patent changes the molecular parameter of ErbB2 regulation by targeting the Erbin binding interface instead of the trastuzumab binding site. This parameter change in the regulatory mechanism allows for differential tissue effects, achieving cancer cell inhibition while preserving cardiac cell function
2Reliability
If ErbB2 activity is inhibited to treat cancer, then tumor progression is reduced, but treatment options remain limited for ErbB2-mediated disorders
Solution Approach 1:
The patent develops Erbin antagonists with universal applicability across multiple ErbB2-mediated disorders including breast cancer, ovarian cancer, and neurological conditions. The single therapeutic approach of disrupting Erbin-ErbB2 interaction demonstrates multi-functionality across different disease contexts where ErbB2 plays a pathological role
Solution Approach 2:
Instead of directly inhibiting ErbB2 kinase activity or blocking ligand binding, the patent inverts the approach by targeting the regulatory protein Erbin that normally stabilizes and activates ErbB2. This inverted strategy provides alternative therapeutic entry points for treating ErbB2-mediated disorders
Data Source
AI summary
Modulating the interaction between ErbB2 and Erbin is an effective method for treating one or more symptoms of ErbB2-mediated disorders. It has been discovered that Erbin stabilizes ErbB2 in vivo and inhibiting the formation of heterodimers between Erbin and ErbB2 reduces or inhibits the biological activity of ErbB2 relative to control levels. Reducing the biological activity of ErbB2 is useful in the treatment of conditions characterized by the overexpression or misregulation of ErbB2. These conditions include, but are not limited to breast cancer and prostate cancer. Alternatively, agonist of Erbin that promote or enhance the interaction of Erbin with ErbB2 can be useful in the treatment of certain neurological disorders. It has also been discovered that Erbin plays a role in the myelination of neurons of the peripheral nervous system.